EFFECT-CRT
Research type
Research Study
Full title
Evaluation of first-phase ejection fraction (EF1) to guide Cardiac Resynchronization Therapy (CRT) - a Randomised Controlled Trial
IRAS ID
353637
Contact name
Haotian Gu
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Cardiac Resynchronization Therapy (CRT) is an effective treatment in patients with severe heart failure. However, even in carefully selected cases, up to 30% of patients fail to respond to this treatment and selection of patients is recognised to be a major challenge. First-phase ejection fraction (EF1) is a simple but novel measure using heart ultrasound detecting early systolic function that may able to identify the suitable patients to respond to CRT. In a retrospective study, we found EF1 to have striking predictive value for response to CRT. Furthermore, improvement of EF1 at 6-months post CRT was a better predictor of clinical outcome than the measures currently used to predict outcomes.
The purpose of the present application is 1) to verify in a multi-centre prospective study that EF1 is sufficiently robustly predictive of CRT response so as to be useful in guiding the selection of patients for CRT; 2) investigate whether EF1 could be used as a target against which CRT parameters can be optimised in a multi-centre RCT; 3) to examine the relationship between global and regional early systolic function to understand how response to CRT relates to these measures.
REC name
London - Westminster Research Ethics Committee
REC reference
25/LO/0562
Date of REC Opinion
10 Sep 2025
REC opinion
Further Information Favourable Opinion